Preventive Care Guidance Released

This afternoon the agencies issued additional ACA guidance in the form of frequently asked questions. This twelfth set of frequently asked questions addresses a number of issues under the preventive care contraceptive requirement. This requirement only applies to non-grandfathered plans.

The guidance confirms that all FDA-approved contraceptives must be provided without cost sharing under the preventive care requirement, not just oral contraceptives as some have suggested. But, more importantly, the guidance also addresses the generic and brand-name drug question with respect to contraceptives. In this regard, the guidance provides that plans may cover a generic contraceptive drug without cost-sharing and impose the regular cost-sharing for branded contraceptive drugs, but with an important caveat. In that case, a plan must accommodate any individual for whom the generic drug (or a brand name drug) would be medically inappropriate, as determined by the individual’s health care provider, by having a mechanism for waiving the otherwise applicable cost-sharing for the branded or non-preferred brand version. Further, if a generic version is not available, or would not be medically appropriate for the patient, then a plan must provide coverage for the brand name drug without cost sharing.

The full version of the guidance can be accessed here.

Latest Thinking

View more Insights
Insights Center
Knowledge assets are defined in the study as confidential information critical to the development, performance and marketing of a company’s core business, other than personal information that would trigger notice requirements under law. For example,
The new study shows dramatic increases in threats and awareness of threats to these “crown jewels,” as well as dramatic improvements in addressing those threats by the highest performing organizations. Awareness of the risk to knowledge assets increased as more respondents acknowledged that their